Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues of timely news and insightful strategies for reducing costs and improving outcomes, delivered by First Class U.S. Mail and electronically,
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
May 20, 2016

Recent Stories

From Drug Benefit News - Cigna Corp. on May 11 revealed it had struck value-based deals with both Amgen and Sanofi/Regeneron Pharmaceuticals, Inc. for their respective PCSK9 inhibitors Repatha (evolocumab) and Praluent (alirocumab), the first major insurer to disclose that it implemented pay-for-performance measures on both of the pricey cholesterol drugs. The contracts provide Cigna a discount on the market price of both drugs — which each came in over $14,000 per patient per year, surpassing analyst expectations — and promise reimbursement for patients whose low-density lipoprotein cholesterol (LDL-C) isn’t lowered as much as was shown in the clinical trials. Read more

Diabetes medications have experienced tremendous price hikes and increases in utilization over… Read more

Following the approval and launch of the first generic of Crestor (rosuvastatin),… Read more

The three largest PBMs posted positive growth numbers for the first quarter… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

May 24, 2016
Medi-Cal Mulls Restarting PBM Bid Process

As Magellan Rx fights for a PBM contract, Medi-Cal considers rejecting all pharmacy bids and starting over.

May 18, 2016
CalPERS Awards $4.9B Drug Benefits Contract to Optum

The CalPERS board voted to award a five-year, $4.9 billion drug benefits contract to UnitedHealth Group's OptumRx, unseating incumbent CVS Health.

May 18, 2016
Key CalPERS Committee Votes for Optum Over CVS

A CalPERS committee voted to award a five-year drug benefits contract to UnitedHealth Group's Optum, unseating incumbent CVS. The full committee is expected to vote today.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?